Referrals for positive tuberculin tests in new health care workers and students: a retrospective cohort study by Xu, Yining & Schwartzman, Kevin
RESEARCH ARTICLE Open Access
Referrals for positive tuberculin tests in new






Background: Documentation of test results for latent tuberculosis (TB) infection is important for health care
workers and students before they begin work. A negative result provides a baseline for comparison with future
tests. A positive result affords a potential opportunity for treatment of latent infection when appropriate. We
sought to evaluate the yield of the referral process for positive baseline tuberculin tests, among persons beginning
health care work or studies.
Methods: Retrospective cohort study. We reviewed the charts of all new health care students and workers referred
to the Montreal Chest Institute in 2006 for positive baseline tuberculin skin tests (≥10 mm). Health care workers
and students evaluated for reasons other than positive baseline test results were excluded.
Results: 630 health care students and workers were evaluated. 546 (87%) were foreign-born, and 443 (70%)
reported previous Bacille Calmette-Guérin (BCG) vaccination. 420 (67%) were discharged after their first evaluation
without further treatment. 210 (33%) were recommended treatment for latent TB infection, of whom 165 (79%)
began it; of these, 115 (70%) completed adequate treatment with isoniazid or rifampin. Treatment discontinuation
or interruption occurred in a third of treated subjects, and most often reflected loss to follow-up, or abdominal
discomfort. No worker or student had active TB.
Conclusions: Only a small proportion of health care workers and students with positive baseline tuberculin tests
were eligible for, and completed treatment for latent TB infection. We discuss recommendations for improving the
referral process, so as to better target workers and students who require specialist evaluation and treatment for
latent TB infection. Treatment adherence also needs improvement.
Background
Tuberculosis (TB) remains a leading cause of morbidity
and mortality worldwide. In 2007, there were an esti-
mated 9.3 million new cases of TB and 1.75 million
resulting deaths [1,2]. In both developing and developed
countries, health care workers and students (HCWS)
represent an important risk group for exposure, infec-
tion, and potentially, disease [3,4]. Although TB in
Canada is rare overall (4.7 cases/100,000 population in
2007) [5], previous studies have highlighted the risks of
TB infection faced by Canadian health care workers
[6,7]. After a few highly publicized active TB cases in
health care workers [8,9], some have called for mass
treatment of latent TB infection in this group [9,10].
Current Canadian guidelines for TB screening among
HCWS call for a baseline two-step tuberculin skin test
(TST). A result of ≥10 mm on the first or second test is
considered positive, triggering referral for chest radio-
graphy and medical evaluation–to identify persons with
active disease, and potential candidates for treatment of
latent TB infection (LTBI). All HCWS with negative
baseline tests will subsequently undergo repeat skin test-
ing for detection of newly acquired infection, which is a
priority for treatment. Repeat skin testing may be done
routinely, or after specific TB exposures of concern
[10,11]; annual chest radiography is not recommended.
Baseline screening is also useful to identify HCWS with
positive tuberculin skin tests but little risk for
* Correspondence: kevin.schwartzman@mcgill.ca
1Montreal Chest Institute, Rm K1.21, 3650 St. Urbain St, Montreal, Quebec,
Canada H2X 2P4
Xu and Schwartzman BMC Public Health 2010, 10:28
http://www.biomedcentral.com/1471-2458/10/28
© 2010 Xu and Schwartzman; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.progression to active TB, who can be discharged from
further evaluation when appropriate [11,12].
In Canada, the standard treatment for LTBI is 9
months of daily isoniazid (INH), with 6 months of daily
INH or 4 months of daily rifampin considered accepta-
ble alternatives [11-13]. These regimens are associated
with frequent minor side effects–and rarely, with severe
hepatotoxicity, a risk that increases with age[14]. Hence,
Canadian HCWS aged ≥35 years with positive baseline
tuberculin tests but normal chest radiographs, are not
candidates for treatment of LTBI in the absence of
other medical risk factors for TB reactivation. More
generally, the long treatment course and the frequency
of side effects pose substantial challenges in ensuring
adherence and successful completion.
In Canada, a further complicating factor is that many
HCWS have emigrated from high TB incidence coun-
tries: in a multi-centre Canadian survey the overall pro-
portion of foreign-born health care workers was 21%; it
was much higher in some cities [15,7]. Foreign-born
HCWS may already have acquired latent TB infection
even without previous health care work. In addition,
interpretation of TST results in the foreign-born may be
confounded by previous Bacille Calmette-Guérin (BCG)
vaccination, which can cause initial positive TST results,
or positive “second-step” (booster) reactions [16,17].
Although previous studies have focused on the yield of
screening and treatment of latent TB infection in
HCWS [18-24], few studies have specifically addressed
the efficiency of baseline TST screening for future
HCWS. The aim of this study was to describe the
demographic, clinical and radiographic characteristics of
HCWS in Montreal with positive baseline tuberculin
tests, as well as the diagnostic and treatment outcomes
of the referral process.
Methods
In this retrospective cohort study, we reviewed the stan-
dardized report forms for TB referrals at the Montreal
Chest Institute (MCI), for positive baseline tuberculin
tests among HCWS. We reviewed all such referrals for
calendar year 2006, to allow complete capture of all sub-
sequent treatment outcomes. Workers and students
evaluated for reasons other than baseline positive tests
were excluded. Demographic and clinical data, diagnos-
tic test results, eligibility for treatment of LTBI, and
treatment outcomes were entered into a Microsoft
Access® database. When the examining physician specifi-
cally attributed a positive tuberculin test to BCG vacci-
nation, this was noted. Adequate treatment for LTBI
was defined as, at least 6 months of isoniazid or 4
months of rifampin [11], based on prescriptions, clinic
attendance, and documentation by physicians and
nurses.
We used STATA statistical software (Version SE8,
College Station, Texas) for descriptive statistics and
bivariate comparisons (Student’s t-test for comparison
of means, chi-squared test for proportions). Subjects
with missing data were excluded from analyses involving
the missing variables, but were retained for other ana-
lyses. This study was approved by the Research Ethics
Board of the McGill University Health Centre.
Results
A total of 633 persons met study inclusion criteria
(Table 1). Over two-thirds were female, and mean age
was 33 years. There were 42 subjects (6.7%) who
reported previous health care work outside Canada, this
included 18 (2.9%) nurses and 11 (1.7%) physicians. Of
124 (20%) who had already begun health care work in
Montreal, the professions most frequently listed were
paramedic/ambulance technician (37; 5.9%) and orderly
(16; 2.5%); current job was not specified for 48 (7.6%).
Among the 478 students, the training programs most
frequently listed were nursing (87/478; 18%), nursing
assistant (58; 12%), orderly (42; 8.8%); there were 12
(2.5%) medical students; and 190 (40%) did not specify
program.
Of the 546 foreign-born subjects: 313 (57%) were born
in countries with annual TB incidence ≥100 active TB
cases/100,000 population, while 184 (34%) were born in
countries with an incidence of 25-99/100,000 [1]; 382
(70%) reported prior BCG vaccination; 43 (7%) reported
known TB exposure; 9 (1.5%) reported previous treat-
ment for active TB; and 6 (1.0%) reported previous
treatment for latent TB infection.
Quantitative results for at least one TST were avail-
able for 615 subjects: 478 (78%) had ≥10 mm induration
on their first test; and over 90% of the remaining sub-
jects had ≥10 mm induration on a second TST after a
first test considered negative. There were 105 (17% of
those with quantitative skin test results) who met Cana-
dian criteria for boosting on the second test [11]; and 8
had their first tuberculin test documented simply as
“negative,” with quantitative results available for the sec-
ond tuberculin test only.
Nearly all subjects denied any symptoms, but 84 (13%)
reported at least one underlying medical condition,
most commonly asthma/allergy and hypertension, and 8
(1.3%) reported medical conditions associated with ele-
vated risk of TB reactivation: 6 diabetics, 1 with renal
disease, and 1 with HIV infection. Only 28 (4.5%) had
radiographs compatible with previous (inactive) TB scar-
ring. One person had a radiograph consistent with pos-
sible active TB and underwent further microbiologic
investigation, but did not have active disease.
The physicians’ final diagnoses and treatment recom-
mendations are summarized in Figure 1. The 210
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significantly younger than the 161 patients judged to
have LTBI but not recommended for treatment (mean
28.0 vs. 39.1 years, P < 0.0001 by Student’s t-test). Of
the 161 for whom treatment was not recommended,
124 (77%) were aged ≥35 years. Among the untreated
group with LTBI: 6 reported previous treatment for
active TB, 5 reported previous treatment for LTBI; 1
was about to move away, 1 wished to become
pregnant, and 1 had underlying liver disease. There
were no other significant demographic features distin-
guishing treated vs. untreated patients with latent TB.
Of note, 9 persons aged ≥35 years were treated despite
normal chest radiographs and no relevant medical con-
ditions. These individuals may have requested treat-
ment despite being older than the usual age threshold
in this context.
Of those who were offered treatment for latent TB,
21% refused; these individuals were even more likely to
report prior BCG vaccination than were those who
accepted treatment. Of the subjects who refused treat-
ment, 31 out of 45 (69%) had a history of BCG vacci-
nation, whereas only 83 (50%) of 165 patients who
started treatment (P = 0.03 by chi-square test)
reported BCG vaccination. Those who refused treat-
ment may have judged that their positive tuberculin
tests reflected their prior vaccination, or perhaps they
believed that protection by the vaccine made treatment
unnecessary [20]. Subjects who refused treatment did
not differ from those who began it, with respect to
age, sex, foreign birth, TB incidence in country of ori-
gin, or duration of residence in Canada (detailed data
not shown).
Of 210 HCWS prescribed treatment, 165 (79%) began
treatment and 115 (70%) of these completed adequate
treatment. Of those prescribed isoniazid, 74 (60%) of
124 completed treatment. Of those prescribed rifampin,
31 (76%) of 41 completed treatment (P = 0.07, chi-
square test). Due to side effects, 8 who began isoniazid
completed treatment after changing to rifampin, and 2
who began rifampin completed treatment after changing
to isoniazid
Treatment interruption or early discontinuation
occurred in 62 (38%) of those treated (Figure 1), most
often because of default or non-adherence (26 subjects).
Subjects who interrupted treatment, or discontinued it
early, were of similar age to completers: mean age 27.5
years for interrupters vs. 28.0 years for completers. The
proportion of females who interrupted treatment was
38% vs. 23% for males (P = 0.05 by chi-square test).
Treatment interruption was no more frequent in sub-
jects aged >35 than in younger subjects (37% vs. 33%).
No subject developed clinical hepatotoxicity or transa-
minases ≥3× the upper limit of normal.
Discussion
Two thirds of new health care workers and students
evaluated for positive tuberculin skin tests were dis-
charged from a tuberculosis referral centre without
treatment. The evaluating physicians judged that many
tests were false positives reflecting previous BCG vacci-
nation - and that most patients were at low risk of reac-
tivation even with true latent infection. A minority of
Table 1 Summary of Patient Characteristics
Patient Characteristics N (SD or %)
Age, years, mean (SD) 33.4 (9.5)
Sex, Female 437/630 (69%)
Foreign Born 546/630 (87%)
Mean years in Canada, if foreign-born (SD) 8.0 (8.3)
WHO Regions of birth, if foreign born
Americas 209/546 (38%)
Africa 101/546 (19%)
Eastern Mediterranean 86/546 (16%)
Europe 78/546 (14%)
Western Pacific 63/546 (12%)
South-East Asia 9/546 (2%)
Reason for Screening
Before health care work 65/630 (10%)*
Before health care studies 478/630 (76%)*























Any Symptoms 12/630 (2%)
Any Concomitant Medical Conditions 84/630 (13%)
Any Regular Medications 136/630 (22%)
Any Smoking History 85/630 (14%)
Any Physical Examination Finding 18/630 (3%)
CXR: Normal 564/630 (90%)
Minor Abnormality 28/630 (4%)
Inactive TB 28/630 (4%)
Possible Active TB 1/630 (0.2%)
Non TB related Abnormality 6/630 (1%)
Pregnant (No CXR) 3/630 (0.5%)
*Some had more than one reason for screening
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students evaluated at the Montreal Chest Institute for positive baseline tuberculin tests, 2006. Abbreviations: LTBI = latent tuberculosis infection,
INH = isoniazid, TST = tuberculin skin test, BCG = Bacille Calmette-Guérin.
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ings which would increase future TB risk were uncom-
mon, and no cases of active TB were identified. One-
third of subjects were deemed eligible for treatment of
latent infection. Of these, 79% began treatment.
Although 70% of subjects who started therapy for latent
TB completed their treatment, this was only 18% of all
subjects referred.
This was a retrospective study, so we were limited to
information documented during routine patient care
rather than data collected specifically for our objectives.
As we could only review files of those persons who were
referred to, and showed up at the MCI, we could not
assess the yield of the initial phases of TST reading and
referral. We could not estimate the proportion of base-
line tests which were positive: the fact that 59% of sub-
jects were considered to have latent TB reflected only
HCWS referred for positive tuberculin tests, most of
whom came from countries with high TB incidence. We
were also unable to compare referred HCWS with peers
who had negative baseline tests, and we could not cap-
ture individuals who did not make or keep their initial
appointments after a positive test.
This study only considered patients seen at a single
TB referral centre, and is not representative of all
patients or practitioners. It is unlikely that the process
is more efficient in primary care clinics or occupa-
tional health offices. The rate of treatment initiation
was consistent with that reported elsewhere [18].
When subjects with latent TB were not offered treat-
ment, the major reason appears to have been age with
attendant toxicity risk, although this was not explicitly
documented by the examining physicians. We did
account for documented patients’ refusal of treatment.
However, it remains possible that some patients made
it clear from the outset that they would not accept
treatment for latent TB; no prescription was offered by
the treating physician but the patient’sr e f u s a lm a yn o t
have been documented.
A strength of this study was the diverse population
of health care workers and students, evaluated conse-
cutively in a real-life practice setting. This differs from
clinical trials, where subjects may be unrepresentative
with respect to their demographic and clinical profile,
and their adherence. Another strength was the physi-
cians’ use of a standardized form for patient evalua-
tions. Patients were managed by a small group of
physicians and nurses with substantial experience in
TB care. Although suboptimal, the 70% completion
rate for treatment of latent TB infection compared
favourably with previous reported values among health
care workers, which have ranged from 38-66%
[18,22-24].
In our study, the physicians’ approach differed from
t h a ta d v o c a t e db yt h eU . S .I n s t i t u t eo fM e d i c i n ew h i c h
recommends that treatment of latent tuberculosis infec-
tion should be widely expanded [25]. Salpeter and Salp-
eter suggested that screening and treatment for LTBI
for all HCWS was cost saving, based on optimistic
assumptions about cost and completion rates for INH
treatment [19]. Based on this study and on earlier cost
data from the MCI [26-28] in Montreal, the cost per
case prevented through baseline screening and treat-
ment of HCWS was likely to exceed considerably the
cost of treating an active TB case.
Nonetheless, beyond the direct cost of treatment there
are many good reasons to prevent TB in health care
workers–including transmission to other workers as well
as patients. However, the yield and efficiency of the
referral program would be substantially enhanced by
reducing unnecessary evaluation of persons who are not
treatment candidates, and by ensuring completion of
treatment by those who are.
A more practical and potentially cost-effective
approach might be to limit referrals for further evalua-
tion and treatment after a baseline positive tuberculin
test, supplemented by a simple clinical questionnaire
and chest radiograph. For example, referrals might be
limited to 1) the small number of symptomatic indivi-
duals; 2) persons with comorbid conditions or radio-
graphic findings that place them at increased risk of
future TB disease; 3) persons <35 years of age, who are
at lowest risk for treatment toxicity.
One solution would be a protocol for occupational
health nurses, whereby asymptomatic workers aged ≥35
with baseline positive tuberculin tests but no medical
risks and normal chest radiographs could be discharged
- since ordinarily, they would not be treated. This group
represented almost 40% of our cohort. Similarly, work-
ers with booster reactions on 2-step tuberculin testing
(10% of our cohort) could also be discharged by nurses,
if their radiographs are normal and they have no other
medical risks. Lambert and colleagues identified person-
nel costs, training and education as the major cost dri-
vers of a TST screening program [21]. Implementation
of a protocol of this type could reduce superfluous eva-
luations by TB specialists, and reduce costs.
Another alternative is to incorporate interferon-
gamma release assays (IGRAs) into the baseline testing
algorithm. U.S. guidelines suggest that IGRAs may be
substituted for baseline and follow-up tuberculin skin
tests among health care workers [11]. These blood tests
require only a single testing visit and eliminate con-
founding by prior BCG vaccination, but are substantially
more expensive than the tuberculin skin test [27]. To
t h ee x t e n tt h a tt h e yr e d u c eu n n e c e s s a r yt e s t i n ga n d
Xu and Schwartzman BMC Public Health 2010, 10:28
http://www.biomedcentral.com/1471-2458/10/28
Page 5 of 7treatment, and promote uptake, [29] this could offset
the costs of the assays themselves and enhance their
cost-effectiveness in this setting [27,30]. Physicians and
patients may be more likely to initiate treatment if they
trust that BCG effect has been excluded. This is particu-
larly relevant, since in our study prior BCG vaccination
was associated with HCWS’ refusal to begin therapy.
Revised Canadian guidelines (2008) suggest that tuber-
culin skin testing should remain the primary screening
modality for Canadian workers, with IGRAs reserved for
confirmation of positive tuberculin test results in low-
risk workers [31]. As with the U.K. NICE guidelines
[32], the Canadian guidelines reflect the fact that data
are only now emerging, with respect to the positive pre-
dictive value of the IGRAs for subsequent development
of active TB [33]. Guidelines also reflect the limited
information currently available to guide interpretation of
serial IGRA results. A recent South African study
demonstrated substantial test-retest variability for
IGRAs among health care workers, highlighting chal-
lenges in interpreting serial tests [34].
For baseline testing, a practical approach would be to
confirm TST results ≥10 mm with an IGRA at the time
of TST reading [34] for BCG-vaccinated HCWS from
lower-incidence countries. Our findings suggest that
some “false-positive” referrals could be avoided by using
IGRAs to supplement the baseline TST in this manner.
Workers with negative IGRA results could then be dis-
charged by the occupational health nurse. More defini-
tive data about the conduct and interpretation of serial
interferon-gamma release assays will be particularly
important in guiding future practice [35].
Conclusions
The documentation of tuberculin skin test results is
important for all persons beginning health care work.
However, in our setting, the yield of current practices
for referral and evaluation following baseline positive
tests appeared limited. There is room for improvement
in targeting evaluation and treatment, and in completion
of treatment for latent TB infection when prescribed.
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